Melanotan II: difference between revisions
Diff·revision 4 → 5·15:25, 24 Dec 2024
Difference between revision 4 and revision 5 of Melanotan II. 4 lines changed; the page grew by 541 bytes.
| Revision 4 — 06:51, 14 Dec 2024 PriorAuthPaz (talk) sentence case in headings per PP:MOS 1,970 bytes ±0 | Revision 5 — 15:25, 24 Dec 2024 StubSorterBot (talk) bot: add stub category 2,511 bytes +541 | ||
|---|---|---|---|
| 11 | Non-selectivity is the defining property. Agonism at MC1R produces melanogenesis, the effect for which it is sought; agonism at MC4R affects appetite and sexual function; agonism at MC3R and MC5R contributes further effects. A single compound producing all of them simultaneously is a pharmacological blunt instrument.{{r|hadley2005}} | 11 | Non-selectivity is the defining property. Agonism at MC1R produces melanogenesis, the effect for which it is sought; agonism at MC4R affects appetite and sexual function; agonism at MC3R and MC5R contributes further effects. A single compound producing all of them simultaneously is a pharmacological blunt instrument.{{r|hadley2005}} |
| 12 | 12 | ||
| + | 13 | Documented harms include nausea and vomiting, spontaneous erections, darkening and change of pigmented lesions, and case reports of melanoma diagnosed in users — the last of which is confounded by the underlying reason people seek tanning and by increased dermatological attention.{{r|cardones2009}} | |
| + | 14 | ||
| 13 | == Pharmacology == | 15 | == Pharmacology == |
| 14 | The melanocortin system comprises five receptors with distinct distributions. MC1R on melanocytes controls the switch between pheomelanin and eumelanin synthesis; MC4R in the hypothalamus is central to appetite regulation and is the target of approved anti-obesity compounds in rare genetic conditions. See [[Arcuate nucleus]].{{r|cone2005}} | 16 | The melanocortin system comprises five receptors with distinct distributions. MC1R on melanocytes controls the switch between pheomelanin and eumelanin synthesis; MC4R in the hypothalamus is central to appetite regulation and is the target of approved anti-obesity compounds in rare genetic conditions. See [[Arcuate nucleus]].{{r|cone2005}} |
| ⋮ | ⋮ | ||
| 19 | {{reflist}} | 21 | {{reflist}} |
| 20 | <ref name="hadley2005">Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." ''Peptides'' 26(10):1687–1689 (2005). PMID 16112778.</ref> | 22 | <ref name="hadley2005">Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." ''Peptides'' 26(10):1687–1689 (2005). PMID 16112778.</ref> |
| + | 23 | <ref name="cardones2009">Cardones AR, Grichnik JM. "α-Melanocyte-stimulating hormone-induced eruptive nevi." ''Archives of Dermatology'' 145(4):441–444 (2009). PMID 19380667.</ref> | |
| 21 | <ref name="cone2005">Cone RD. "Anatomy and regulation of the central melanocortin system." ''Nature Neuroscience'' 8(5):571–578 (2005). PMID 15856065.</ref> | 24 | <ref name="cone2005">Cone RD. "Anatomy and regulation of the central melanocortin system." ''Nature Neuroscience'' 8(5):571–578 (2005). PMID 15856065.</ref> |
| 22 | 25 | ||
| ⋮ | ⋮ | ||
| 24 | [[Category:Melanocortin agonists]] | 27 | [[Category:Melanocortin agonists]] |
| 25 | [[Category:Research peptides]] | 28 | [[Category:Research peptides]] |
| + | 29 | [[Category:Articles describing unapproved compounds]] | |
| 26 | 30 |